BioMed Research International / 2017 / Article / Tab 1

Research Article

A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy

Table 1

The clinical characteristics of the patients.

Total ()High PMI ()Low PMI () value

Age (years)
 <6513 (48.1%)7 (53.8%)6 (42.9%)0.568
 ≥6514 (51.9%)6 (46.2%)8 (57.1%)
Gender
 Female6 (22.2%)3 (23.1%)3 (21.4%)0.918
 Male21 (77.8%)10 (76.9%)11 (78.6%)
Creatinine clearance (mL/min.)
 <6012 (44.4%)6 (46.2%)6 (42.9%)0.8632
 ≥6015 (55.6%)7 (53.8%)8 (57.1%)
Cystectomy or nephroureterectomy
 Yes16 (59.3%)10 (76.9%)6 (42.9%)0.0719
 No11 (40.7%)3 (23.1%)8 (57.1%)
Response after 2 courses of GN therapy
 CR and PR13 (48.1%)10 (76.9%)3 (21.4%)0.0719
 SD and PD14 (51.9%)6 (46.2%)8 (57.1%)
Adverse effects (grade ≥ 3)
 Neutropenia25 (92.6%)12 (92.3%)13 (92.9%)0.9566
 Thrombocytopenia17 (63.0%)8 (61.5%)9 (64.3%)0.6802
 Appetite loss or nausea1 (3.7%)1 (7.7%)0 (0%)0.2903